載入中
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
前收盤價
US$5.07
+US$0.17 · +3.47%
盤中時間採用ET。市場資料可能有所延遲。
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
日內區間
目前US$5.07
52週區間
目前US$5.07
盤中時間採用ET。市場資料可能有所延遲。
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
日內區間
目前US$5.07
52週區間
目前US$5.07
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | — | — | 172.1萬 USD | 111.8萬 USD |
| 毛利 | — | — | — | −172.1萬 USD | −111.8萬 USD |
| 研究與開發 | 2380.7萬 USD | 2281.1萬 USD | 1614.8萬 USD | 2799萬 USD | 3042.3萬 USD |
| 銷售、一般及管理費用 | 916萬 USD | 521.8萬 USD | 671.9萬 USD | 1089.8萬 USD | 1245.2萬 USD |
| 營業費用 | 3296.7萬 USD | 2802.9萬 USD | 2286.7萬 USD | 3716.7萬 USD | 4202.7萬 USD |
| 利息收入 | — | 44.2萬 USD | 54.8萬 USD | 26.7萬 USD | 46.8萬 USD |
| 利息支出 | 68.5萬 USD | 152.5萬 USD | 171.1萬 USD | 133.9萬 USD | — |
| 折舊和攤銷 | 145.8萬 USD | 162.2萬 USD | 182.2萬 USD | 172.1萬 USD | 111.8萬 USD |
| 營業利益 | −3296.7萬 USD | −2802.9萬 USD | −2286.7萬 USD | −3888.8萬 USD | −4314.5萬 USD |
| 淨利 | −3416.9萬 USD | −2902.2萬 USD | −2386.5萬 USD | −3952.5萬 USD | −4071.3萬 USD |
公司資料更新於 2026年10月11日。
第三方分析師預期可能變動，並非 GoAI 建議。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
